The recent announcement that scientists have made human-monkey embryos and cultured them in the lab for two weeks made international headlines.
The technology to make animals that contain cells from other species has been available for decades and used extensively in research. These organisms are called chimeras.
But this latest advance highlights the need to broaden the discussion around the possible benefits of such research and, specifically, how inter-species chimeric research should be conducted in future.
Human-animal chimeras blur the line about what it means to be human, and this raises serious ethical questions about how we should use them.
Human-monkey chimeras were first made in 2019. Inter-species chimeras are made by mixing cells belonging to one species with those of another.
This usually involves conducting microsurgery to introduce pluripotent stem cells which can develop into several different types of cells into a host embryo from another species.
In the recent study, human stem cells were placed inside six-day-old monkey embryos created by fertilisation. The human-monkey embryos comprised mostly of monkey cells and some human cells.
These embryos were then kept in a laboratory, where researchers monitored the interactions between the human and monkey cells for up to 14 days, although most embryos didnt survive.
Some will find the idea of mixing human cells with any animal embryo (let alone a primate embryo) highly questionable. For the researchers who led the study, the rationale was clear.
They were interested in addressing the shortage of life-saving organs for human transplantation. If done successfully, a chimera could grow an organ suitable for direct transplant into a human.
Researchers have previously created human-pig chimeras, where pig embryos containing human cells were allowed to grow into a foetus.
However, the contribution of human cells was low and the goal to create transplantable organs remained elusive. The question of how to solve this challenge is what led to the recent experiment.
Read more: What's the benefit in making human-animal hybrids?
In this recent study, researchers werent attempting to create human-monkey chimeras with a view to harvest organs. Rather, they created an in-vitro model (outside a living organism) to explore what happens to the transferred human cells.
They wanted to identify ways to enhance the survival of the human cells and ultimately improve human chimerism in pigs and other evolutionarily-distant species, with a view to developing transplantable human organs from animal donors.
This project might conjure images of mad scientists (think Victor Frankenstein) meddling with nature, irresponsible and without oversight. But unlike Frankensteins experiments, this study was not done in secret.
In the paper, the researchers describe in detail the steps they took to comply with international guidelines. This included extensive ethics reviews undertaken within the institutions involved and consultation with external bioethicists.
Of note, the study involved the use of eggs harvested from female monkeys. While the animals werent killed, any use of non-human primates should be approached conservatively and be consistent with international standards.
Research involving non-human primates is carefully scrutinised. Such projects receive special consideration from regulatory bodies and ethics committees around the world.
Nonetheless, even when conducted with ample oversight, human-animal chimera research does raise ethical questions.
The thorniest ones are linked not to the creation of in-vitro chimeric embryos, but rather the eventual creation of live-born chimeras, such as a human-pig chimera, if future research can overcome current limitations.
Read more: Fully-grown pig chimeras are only a few years away we need to understand where they stand now
Humans are widely (but not universally) thought to have a higher moral status than other animals. But human-animal chimeras blur this line. They are not fully human, nor fully non-human.
So the big question is whether (or under what conditions) we should be allowed to use them as a source of transplantable organs, in harmful research, or for other purposes we wouldnt use humans for.
These concerns will be most acute for chimeras with human-like brains, wherein human cells are incorporated into an animals brain during development.
Humans pride themselves on their autonomy, rationality and sophisticated self-awareness. If a human-pig chimera developed this capacity, it may have a moral claim to be treated more like a human than a pig.
The study raises a second ethical concern that is more immediately relevant. Using recent advances in monkey-embryo culture, the researchers cultured some embryos until 19 days post-fertilisation.
Many jurisdictions explicitly limit human embryo research to the first 14 days of development, when what will become the central nervous system begins to develop.
Should the 14-day limit also apply to human-animal chimeric embryos?
Perhaps it should depend on the proportion of human cells in developing chimeric embryo. Although, this leaves us with the question of how many human cells is too many.
Or perhaps, as some have argued, the 14-day rule ought to be revised.
Like many other aspects of stem cell research, we can find a starting point in guidelines from the International Society for Stem Cell Research.
These standards, soon to be updated, explicitly recommend specialised review for human-animal chimera research. This includes monitoring chimeric animals for unexpected behaviours that indicate suffering, which could then be addressed under existing animal ethics principles.
Experts say it might be worth monitoring chimeric animals for evidence they may be autonomous, rational, or self-aware and modifying their treatment accordingly.
Given the ethical complexity and sensitivity of human-animal chimera research, its crucial it receives careful oversight. As the field develops we must continuously review where the boundaries of the research lie.
And these conversations must not only explore animal welfare, but also how potential patients and the broader community view access to organs derived from donor animals.
Originally posted here:
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments